Yahes provided first quarter 2026 guidance of total revenues between $480 million and $490 million and adjusted EBITDA of $105 million to $110 million. Grow segment is forecast to be flat sequentially ...
CRISPR gene editing and next-generation sequencing (NGS) have transformed clinical and life sciences research. CRISPR permits the selective targeting and editing of specific nucleotide sequences, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results